What We Do
At InkVivo Technologies, we develop next-generation drug delivery solutions that improve therapeutic outcomes and patient quality of life. Our proprietary polymer platform enables controlled, localized, and sustained release of active ingredients—ranging from small molecules to biologics—across oral and injectable routes.
By combining advanced biomaterials, data-driven formulation design, and scalable manufacturing, we aim to help pharmaceutical and nutraceutical partners that want to enhance bioavailability, reduce dosing frequency, and minimize side effects. This approach has the potential to improve patient adherence and also supports lifecycle extension and differentiation for existing products.
Our mission is clear: to bridge science and industry with innovative technologies that set new standards in drug delivery.
Learn More
Our Solutions
Innovative drug delivery technologies with the goal to enhance bioavailability, improve patient adherence, and accelerate product development.
With GARDS and SHEALD we bring gastroretentive and injectable drug delivery to the next level.
Disease Areas
Targeting high-impact and unmet needs with advanced delivery systems that improve efficacy, safety, and patient adherence.
Collaborations
Collaborate with us to accelerate innovation and develop next-generation medicines.
Latest News
InkVivo secures CHF 1.1 Million pre-seed financing
Exciting news: InkVivo has raised CHF 1.1M to reinvent how medicines are delivered.
Our polymer-based formulation platform aims to make treatments more effective, longer-lasting, and easier for patients, while giving pharma partners faster development and new IP opportunities.
Backed by Tiventures SA, Claves Investments, and seasoned business angels, we’re now accelerating:
💊 Clinical development of our lead anemia treatment
🤝 New pharma & nutraceutical collaborations
The future of smart drug formulation starts here
InkVivo selected for Venture Leaders Biotech 2025
InkVivo has been selected to explore the US biotech ecosystem in Summer 2025.
“Ten startups have been selected for the 2025 Venture Leaders Biotech program, which will take them to Boston from June 23rd to 27th as part of the Swiss National Startup Team. During their roadshow, the entrepreneurs will connect with international investors and industry leaders, acquiring expertise to help scale their ventures. Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex Boston & New York and supported by the University of Basel, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.”
InkVivo is now officially an ETH Zurich Spin-off
Good news! InkVivo Technologies AG has been recognized as a spin-off from ETH Zürich. Let’s work together to bring innovative drug delivery systems closer to every patient. For more information contact us! 🚀